Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study
Alternatives to Laboratory Animals · 21.11.2026
DOI: 10.1177/02611929261506474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alternatives to Laboratory Animals, online erschienen am 21.11.2026. Verfasst von Lucie Valkova und 9 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
The rapid emergence of antimicrobial-resistant pathogens and the declining efficacy of conventional antibiotics have intensified the search for alternative therapeutic strategies. PdTPPS 4 (palladium(II) meso-tetra(4-sulphonatophenyl)porphyrin) is a novel water-soluble photosensitiser with promising photodynamic and antibacterial potential. In the current study, the dermatotoxicological profile of this compound was evaluated by using a number of mechanism-informed, validated non-animal methods. The in vitro assays undertaken in the current study were modified to achieve optimised conditions, but were based on the following Organisation for Economic Co-operation and Development (OECD) Test Guidelines: TG 439 ( in vitro skin irritation testing, with reconstructed human epidermis); and, for the evaluation of skin sensitisation potential, TG 442D (specifically, the ARE-Nrf2 luciferase test method (LuSens assay)) and TG 442C (the Direct Peptide Reactivity Assay (DPRA)). An immunoassay-based assessment of early inflammatory biomarkers (IL-1α, IL-18) was also performed, in order to detect potential sub-irritant responses. PdTPPS 4 showed no indication of skin irritation, inflammatory activation or sensitisation potential under the test conditions. These findings support the favourable dermal compatibility of PdTPPS 4 under non-irradiated (dark) conditions, and indicate low intrinsic dermatotoxicity in the tests performed. This study provides initial toxicological evidence supporting further investigation of PdTPPS 4 as a promising candidate photosensitiser, for use in future antimicrobial photodynamic therapy applications. These results not only demonstrate the dermatological safety of PdTPPS 4 , but also introduce a new methodological framework for the preclinical safety screening of photosensitisers by using exclusively non-animal OECD-guided assays. The current non-animal and mechanism-informed assessment of dermal toxicity contributes to both the ethical and translational advancement in the development of photodynamic therapeutic agents, supporting regulatory and clinical decision-making with regard to these compounds.
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Valkova, L., Svobodova, L., Kolarikova, M., Kejlova, K., Bajgar, R., Tomankova, K. B., Dilenko, H., Rucki, M., Bendova, H., & Kolarova, H. (2026). Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study. Alternatives to Laboratory Animals. https://doi.org/10.1177/02611929261506474
Vancouver
Valkova L, Svobodova L, Kolarikova M, Kejlova K, Bajgar R, Tomankova KB, et al. Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study. Alternatives to Laboratory Animals. 2026. doi:10.1177/02611929261506474
BibTeX
@article{Valkova2026,
author = {Valkova, Lucie and Svobodova, Lada and Kolarikova, Marketa and Kejlova, Kristina and Bajgar, Robert and Tomankova, Katerina Barton and Dilenko, Hanna and Rucki, Marian and Bendova, Hana and Kolarova, Hana},
title = {Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study},
journal = {Alternatives to Laboratory Animals},
year = {2026},
doi = {10.1177/02611929261506474}
}
EUVIMED